Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

Investigating GLP-1 RAs reveals their impact on women's health, addressing metabolic disorders, reproductive health, and ...

HealthDay News — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with better graft and patient survival among kidney transplant recipients with diabetes, according to a study ...

HealthDay News — Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize risks for complications, according to a study presented at ...

There is initial evidence that low-dose semaglutide may reduce craving and drinking outcomes in individuals with alcohol-use disorder.

A large population-based cohort study reports that using GLP-1 RAs significantly reduces the risk for cardiovascular events ...

Patients with T2D who undergo kidney transplants are less likely to experience organ failure and mortality if they receive ...

There is unlikely to be an increase in the very low incidence of suicide-related adverse events among individuals receiving ...

“The findings of this cohort study suggest that GLP-1 RAs are associated with reduced risk of developing several hematologic cancers, particularly MDS and MPN, in patients with T2D,” the ...

A MUM’S bid to reclaim her pre-baby body by using a ‘£90 skinny jab’ nearly killed her – after she collapsed vomiting blood.

Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize risks for complications, according to a study presented at the annual ...